Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
To evaluate antibody persistence of Aleph inactivated split influenza vaccine, 3308 healthy Chinese people more than 3 years old were enrolled in a hemagglutination inhibition (HI) assay before vaccination, 641 were screened by HI assay negative, 437 of which received one dose of Aleph inactivated split influenza vaccine and 204 of which received one dose of control vaccine (recombinant hepatitis B). After vaccination, the receivers were collected blood at 1st month, 3rd month, 6th month and 12th month for Aleh influenza vaccine antibody persistence assess. The antibody test were determined by hemagglutination inhibition (HI) assay. There were significant difference in antibody geometric mean titer between experimental group and control at 1st month and 3rd month after vaccination. Influenza antibody could persist at least up to 3rd month. Because of the local spring influenza epidemic, we could not analyze the results of 6th and 12th month. Aleph influenza vaccines showed good immune persistence in healthy volunteers at least in the 3 months after vaccination. Influenza viruses are important human respiratory pathogens. Immunization is widely acknowledged to currently be the most effective method of minimizing the impact of pandemic influenza. Through we have checked many references about Influenza vaccine, the duration of protective antibody for influenza vaccines are still not available. Based on this situation and our previous work, (11) Influenza vaccine antibody duration analyze are necessary. This manuscript presents data on the persistence of Hemagglutination Inhibition (HI) immune response against the A/California/7/2009(H1N1), A/Peth/16/2009(H3N2) strain and B/Brisbane/60/2008. 641 were screened from 3302 volunteers by HI test of influenza A and confirmed enrollment based on the antibodies titer less than 1:10. After administered with one dose of Aleph influenza vaccine, blood samples were collected. 437 subjects (3-10 y: 131; 11-17 y: 110; 18-54 y: 69; ≥ 55 y: 127) were vaccinated influenza vaccine as test group. 204 subjects (3-10 y: 70; 11-17 y: 47; 18-54 y: 28; ≥ 55 y: 59) were vaccinated recombinant hepatitis B vaccine as control group. Immunogenicity end points were based on the European licensure criteria for pandemic influenza vaccines. The persistence of HI immune response against the vaccine strain was assessed through GMT. The immunogenicity of the Aleph influenza vaccine induced all reached the standards at 1st month and GMTs peak could persist at least up to 3rd month. (This study has been registered at clinicaltrials.gov under registration no. NCT01758185.). Because of the local spring influenza epidemic we could not analyze the results of 6th and 12th month. Aleph influenza vaccines showed good immune persistence in healthy volunteers at least in the 3 months after vaccination.
['Bai|Yunhua|Y|', 'Shi|Nianmin|N|', 'Lu|Qiang|Q|', 'Yang|Liqing|L|', 'Wang|Zhaoyun|Z|', 'Li|Li|L|', 'Han|HuiXia|H|', 'Zheng|Dongyi|D|', 'Luo|FengJi|F|', 'Zhang|Zheng|Z|', 'Ai|Xing|X|']
D000293:Adolescent D000328:Adult D000368:Aged D000914:Antibodies, Viral D002648:Child D002675:Child, Preschool D002681:China D004311:Double-Blind Method D005260:Female D064368:Healthy Volunteers D006385:Hemagglutination Inhibition Tests D017325:Hepatitis B Vaccines D006801:Humans D053118:Influenza A Virus, H1N1 Subtype D053122:Influenza A Virus, H3N2 Subtype D009981:Influenza B virus D007252:Influenza Vaccines D007251:Influenza, Human D008297:Male D008875:Middle Aged D012621:Seasons D013997:Time Factors D015164:Vaccines, Inactivated D014614:Vaccines, Synthetic D055815:Young Adult
influenza vaccine HI influenza epidemic immune persistence GMT GMT, Geometric Mean Titer HBV, Hepatitis B virus Vaccine HI, Hemagglutination Inhibition TIV, trivalent inactivated vaccine